Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-10-18
2005-10-18
Tate, Christopher R. (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S012200, C514S021800, C424S085400, C424S085500, C424S085700, C424S085100, C530S406000
Reexamination Certificate
active
06956027
ABSTRACT:
Provided herein are methods and compositions relating to the attachment of water soluble polymers to proteins. Provided are novel methods for N-terminally modifying proteins or analogs thereof, and resultant compositions, including novel chemically modified G-CSF compositions and related methods of preparation.
REFERENCES:
patent: 1609536 (1926-12-01), Harris
patent: 4002531 (1977-01-01), Royer
patent: 4179337 (1979-12-01), Davis et al.
patent: 4609546 (1986-09-01), Hiratani
patent: 4695623 (1987-09-01), Stabinsky
patent: 4766106 (1988-08-01), Katre et al.
patent: 4791192 (1988-12-01), Nakagawa et al.
patent: 4810643 (1989-03-01), Souza
patent: 4833127 (1989-05-01), Ono et al.
patent: 4847325 (1989-07-01), Shadle et al.
patent: 4894226 (1990-01-01), Aldwin et al.
patent: 4897471 (1990-01-01), Stabinsky
patent: 4904584 (1990-02-01), Shaw
patent: 5166322 (1992-11-01), Shaw et al.
patent: 5194592 (1993-03-01), Yoshida
patent: 5214132 (1993-05-01), Kuga et al.
patent: 5218092 (1993-06-01), Sasaki et al.
patent: 5252714 (1993-10-01), Harris et al.
patent: 5281698 (1994-01-01), Nitecki
patent: 5349052 (1994-09-01), Delgado et al.
patent: 5372808 (1994-12-01), Blatt et al.
patent: 5382657 (1995-01-01), Karasiewicz et al.
patent: 5532341 (1996-07-01), Welte et al.
patent: 5581476 (1996-12-01), Osslund
patent: 5672662 (1997-09-01), Harris et al.
patent: 5824778 (1998-10-01), Ishikawa et al.
patent: 5824784 (1998-10-01), Kinstler et al.
patent: 5985265 (1999-11-01), Kinstler et al.
patent: 6027720 (2000-02-01), Kuga et al.
patent: 6166183 (2000-12-01), Ishikawa et al.
patent: A-76380/91 (1991-11-01), None
patent: A-10948/92 (1992-08-01), None
patent: 401 384 (1990-12-01), None
patent: 154 316 (1985-09-01), None
patent: 098 110 (1986-09-01), None
patent: 210 761 (1987-02-01), None
patent: 215 126 (1987-03-01), None
patent: 236 987 (1987-09-01), None
patent: 243 153 (1987-10-01), None
patent: 247 860 (1987-12-01), None
patent: 256 843 (1988-02-01), None
patent: 272 703 (1988-06-01), None
patent: 335 423 (1989-10-01), None
patent: 0 340 741 (1989-11-01), None
patent: 370 205 (1990-05-01), None
patent: 442 724 (1991-08-01), None
patent: 456 200 (1991-11-01), None
patent: 459 630 (1991-12-01), None
patent: 473 268 (1992-03-01), None
patent: 473 769 (1992-03-01), None
patent: 490 584 (1992-06-01), None
patent: 539 167 (1993-04-01), None
patent: 721 958 (1996-07-01), None
patent: 2 193 631 (1988-02-01), None
patent: 57-192435 (1982-11-01), None
patent: 61-42558 (1986-09-01), None
patent: 62-115280 (1987-05-01), None
patent: 62-129298 (1987-06-01), None
patent: 62-236488 (1987-10-01), None
patent: 62-236497 (1987-10-01), None
patent: 62-289522 (1987-12-01), None
patent: 62-503171 (1987-12-01), None
patent: 63-10800 (1988-01-01), None
patent: 63-60938 (1988-03-01), None
patent: 63-500636 (1988-03-01), None
patent: 63-126900 (1988-05-01), None
patent: 1-26677 (1989-05-01), None
patent: WO-87/01132 (1987-02-01), None
patent: WO-89/10932 (1989-12-01), None
patent: WO-89/05824 (1990-02-01), None
patent: WO-90/04606 (1990-05-01), None
patent: WO-90/09798 (1990-09-01), None
patent: WO-90/12874 (1990-11-01), None
patent: WO-91/05798 (1991-05-01), None
patent: WO-92/06707 (1992-04-01), None
patent: WO-94/00913 (1993-12-01), None
patent: WO-96/11953 (1996-04-01), None
Abuchowski, et al., inEnzymes as Drugs,J.S. Holcerberg and J. Roberts (Eds.), pp. 367-383 (1981).
Asano, et al., “A Colorimetric Microassay for the Biological Activity of Human Granulocyte Colony-Stimulating Factor Using Murine Myeoblastic Leukemia, NSF-60 Cells,”Japan Pharmacol. Ther., 19:2767-2773 (1991).
Balmer, DICP,The Annals of Pharmacotherapy,24:761-767 (1990).
Bensinger, et al., “Autologous Transplantation with Peripheral Blood Mononuclear Cells Collected After Administration of Recombinant Granulocyte Simulating Factor,”Blood 81(11):3158-3163 (1993).
Bodine, “Mobilization of Peripheral Blood ‘Stem’ Cells: Where there is smoke, is there fire?”Experimental Hematology 23:293-295 (1995).
Boehringer Mannheim,Biochemica Katalog,pp. 362 (1994).
Brugger, et al., “Mobilization of Peripheral Blood Progenitor Cells by Sequential Administration of Interleukin-3 and Granulocyte-Macrophage Colony-Stimulating Factor Following Polychemotherapy with Etopside, Ifosamide, and Cisplatin,”Blood 79:1193-1200 (1992).
Chamow, et al., “Modification of CD4 immunoadhesion with monomethoxypoly(ethylene glycol) aldehyde via reductive alkylation,”Bioconjugate Chem.,5:133-140 (1994).
CRC Standard Mathematical Tables,26th Ed. (Beyer, W.H. Ed.) CRC Press, Inc., Boca Raton, FL 1981, p. 125.
Delgado, et al. “The Uses and Properties of PEG-Linked Proteins,”Critical Reviews in Therapeutic Drug Carrier Systems 9:249-304 (1992).
Delgado, et al., “Coupling of PEG to Protein by Activation with Treysi Chloride, Applications in Immunoaffinity Cell Preparation,” in Fisher et al., Eds., Separations Using Aqueous Phase Systems, Applications in Cell Biology and Biotechnology, Plenum Press, New York, NY, pp. 211-213 (1989).
Filgrastim Clinical Practice,Morstyn G and T.M. Dexter, eds., Marcel Dekker, Inc., New York NY 1993, p. 351.
Francis, “Protein Modification and Fusion Proteins,”Focus on Growth Factors, 3:4-10 (May 1992).
Francis, et al., inStability of Protein Pharmaceuticals: In Vivo Pathways of Degradation and Strategies for Protein Stabilization,Ahem, T. and Manning, M.C. (Ed.), Plenum Pres, New York, NY (1991).
Gaertner, et al., “Site specific attachment of functionalized poly(ethylene glycol) to the amino terminus of proteins,”Bioconjugate Chem., 7(1):38-44 (1996).
Goodson, et al., “Site-directed Pegylation of recombinant Interleukin-2 at its Glycosylation Site,”Bio/Technology, 8:343-346 (1990).
Habeeb, “Determination of Free Amino Groups in Proteins by Trinitrobenzenesulfonic Acid,”Anal. Biochem., 14:328-336 (1966).
Hershfield, et al., “Treatment of Adenosine Deaminase Deficiency with Polyethylene Glycol-Modified Adenosine Deaminase,”N.E. Journ. of Medicine, 316:589-596 (1987).
Hill, et al., “The structure of granulocyte-colony-stimulating factor and its relationship to other growth factors,”Proc. Natl. Acad. Sci., USA 90(11):5167-5171 (Jun. 1993).
Inada, et al., “Polyethylene Glycol (PEG)-Protein Conjugates: Application to Biomedical and Biotechnological Processes,”J. Bioact. and Compatible Polymers, 5:343-364 (1990).
Ishikawa, et al., “The Substitution of Cysteine 17 of Recombinant Human G-CSF with Alanine Greatly Enhanced its Stability,”Cell Structure and Function, 17(1):61-65 (Feb. 1992).
Katre, “The Conjugation of Proteins with Polyethylene Glycol and Other Polymers,”Advanced Drug Delivery 10:91-114 (1993).
Katre, et al., “Chemical Modification of Recombinant Interleukin 2 by Polyethylene Glycol Increases it Potency in the Murine Meth A Sarcoma Model,”Proc. Nat'l Acad. Sci., USA, 85:1487-1491 (1987).
Klein, et al., “Isolation and structural characterization of Three Isoforms of Recombinant Consensus Alpha Interferon,”Arc Biochem. Biophys., 276:531-537 (1990).
Klein, et al., “Structural Characterization of Recombinant Consensus Interferon-Alpha,”J. Chromatog. 454:205-215 (1988).
Kodera, et al., “Frontier of Chemical Modification of Proteins: Application of Polyethylene glycol-modified Enzymes in Biotechnical Processes,”Seikagaku 60(9):1015-1018 (1988). No English Translation.
Koerholz, et al., “Chemical and Immunological Characteristics of Four Different L-Asparaginase Preparations,”Eur. J. Haematol., 42(5):417-424 (1982).
Kuga, et al., “Mutagenesis of Human Granulocyte Colony Stimulating Factor,”Biochem. Biophys. Res. Commun., 159(1):103-111 (1989).
Laemmli, “Cleavage of Structural Proteins During the Assembly of the Head of Bacteriophage T4,”Nature 227:680-685 (1970).
Lu, et al., “Disulfide and Secondary Structures and Recomb
Amgen Inc.
Chism B. Dell
Marshall & Gerstein & Borun LLP
Tate Christopher R.
LandOfFree
N-terminally chemically modified protein compositions and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with N-terminally chemically modified protein compositions and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and N-terminally chemically modified protein compositions and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3474773